Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target

Benzinga · 01/07 11:34
Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $38 price target.